SynthesisWorld journal of urology2023
Radiomics vs radiologist in prostate cancer. Results from a systematic review.
Synthesis in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Is there a role of PSMA-PET in focal therapy planning and follow-up?Prostate cancer and prostatic diseases · 2026Pooled it
- MRI-based radiomics for prediction of biochemical recurrence in prostate cancer: a systematic review and meta-analysis.Abdominal radiology (New York) · 2025Pooled it
- Clinical application of radiomics for the prediction of treatment outcome and survival in patients with renal cell carcinoma: a systematic review.World journal of urology · 2024Pooled it
- MRI-based radiomics for prediction of extraprostatic extension of prostate cancer: a systematic review and meta-analysis.La Radiologia medica · 2024Pooled it
- Intralesional and perilesional radiomics strategy based on different machine learning for the prediction of international society of urological pathology grade group in prostate cancer.BMC medical imaging · 2025Article
- Biparametric MRI-based radiomics for prediction of clinically significant prostate cancer of PI-RADS category 3 lesions.BMC cancer · 2025Article
- Prostate cancer MRI methodological radiomics score: a EuSoMII radiomics auditing group initiative.European radiology · 2025Review
- Biparametric MRI-based radiomics for differentiating clinically significant prostate cancer among prostate-specific antigen level of gray zone.Frontiers in oncology · 2025Article
- Interpretable machine learning model for predicting clinically significant prostate cancer: integrating intratumoral and peritumoral radiomics with clinical and metabolic features.BMC medical imaging · 2024Article
- Article
- Radiomics Beyond the Hype: A Critical Evaluation Toward Oncologic Clinical Use.Radiology. Artificial intelligence · 2024Review
- Review
- Development and validation of a clinical-radiomics model for prediction of prostate cancer: a multicenter study.World journal of urology · 2024Article
- Review
- Minimally Invasive Urological Procedures and Related Technological Developments-Series 2.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadiomics in uro-oncology is a rapidly evolving science proving to be a novel approach for optimizing the analysis of massive data from medical images to provide auxiliary guidance in clinical issues. This scoping review aimed to identify key aspects wherein radiomics can potentially improve the accuracy of diagnosis, staging, and extraprostatic extension in prostate cancer (PCa).
methodsThe literature search was performed on June 2022 using PubMed, Embase, and Cochrane Central Controlled Register of Trials. Studies were included if radiomics were compared with radiological reports only.
resultsSeventeen papers were included. The combination of PIRADS and radiomics score models improves the PIRADS score reporting of 2 and 3 lesions even in the peripheral zone. Multiparametric MRI-based radiomics models suggest that by simply omitting diffusion contrast enhancement imaging in radiomics models can simplify the process of analysis of clinically significant PCa by PIRADS. Radiomics features correlated with the Gleason grade with excellent discriminative ability. Radiomics has higher accuracy in predicting not only the presence but also the side of extraprostatic extension.
conclusionsRadiomics research on PCa mainly uses MRI as an imaging modality and is focused on diagnosis and risk stratification and has the best future possibility of improving PIRADS reporting. Radiomics has established its superiority over radiologist-reported outcomes but the variability has to be taken into consideration before translating it to clinical practice.
Indexed as
Identifiers
36867239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.